Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Betaliq
AddedFeb 15, 2024
UpdatedJun 18, 2026
Betaliq

Betaliq

Betaliq, a Novaliq and BLP collaboration, innovates glaucoma treatment with patented EyeSol technology.

HQ
Tampa, FL, US
Founded
2018
Overview
Compare
Fundraising
Employees

Betaliq, a collaboration between Novaliq and BLP Management Group, focuses on innovating glaucoma treatment using Novaliq’s patented EyeSol non-water formulation technology. The company is developing two beta-blockers: BTQ 1901, a new selective beta-blocker for glaucoma, and BTQ 1902, an EyeSol-based formulation of the widely prescribed timolol.

Betaliq has made significant strides in ophthalmic treatment by leveraging EyeSol technology to enhance drug delivery and efficacy. The collaboration between Novaliq and BLP has positioned Betaliq as a promising player in the glaucoma treatment market, aiming to improve patient outcomes with advanced formulations.

Betaliq - Similar Companies

Adtech Pharma logo

Adtech Pharma

adtechpharma.com

TherOptix logo

TherOptix

Hyperion DeFi logo

Hyperion DeFi

eyenovia.com

Visus Therapeutics logo

Visus Therapeutics

visustx.com

Ocular Therapeutix logo

Ocular Therapeutix

ocutx.com

Spyglass Pharma logo

Spyglass Pharma

spyglasspharma.com

OcuTerra Therapeutics logo

OcuTerra Therapeutics

ocuterratx.com

Iacta Pharmaceuticals logo

Iacta Pharmaceuticals

Solx logo

Solx

Myra Vision logo

Myra Vision

myravision.com

Eye-Pharma logo

Eye-Pharma

TearClear logo

TearClear

tearclear.com

Iantrek logo

Iantrek

iantrekmed.com

EyeScience Labs logo

EyeScience Labs

Eyebot logo

Eyebot

eyebot.tech

Betaliq - Quick Facts

Who are Betaliq's competitors?

Companies similar to Betaliq include Adtech Pharma, TherOptix, Hyperion DeFi and Visus Therapeutics.

When was Betaliq founded?

Betaliq was founded in 2018.

Where is Betaliq's headquarters located?

Betaliq's headquarters is located in Tampa, FL, US.

When was Betaliq's last funding round?

Betaliq's most recent funding round was for $6M (USD) in April 2019.

How much has Betaliq raised to-date?

As of Apr 29, 2019, Betaliq has raised a total of $6M (USD).

How many employees does Betaliq have?

Betaliq has 5 employees as of Feb 5, 2024.

Betaliq - Classification

Ownership
  • Private
Technology
  • Biotech
  • HealthTech
Revenue
  • Recurring
Main Product
  • Glaucoma Treatment
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541714Research and Development in Biotechnology (except Nanobiotechnology)
  • 541000Professional, Scientific, and Technical Services
  • 541700Scientific Research and Development Services
  • 541710Research and Development in the Physical, Engineering, and Life Sciences
SIC
  • 8700Engineering, Accounting, Research, Management, And Related Services
  • 8730Research, Development, And Testing Services
  • 8731Commercial Physical and Biological Research
Show 12 more industry codes
NAICS
  • 320000Manufacturing
  • 325400Pharmaceutical and Medicine Manufacturing
  • 620000Health Care and Social Assistance
  • 325000Chemical Manufacturing
  • 325410Pharmaceutical and Medicine Manufacturing
  • 325412Pharmaceutical Preparation Manufacturing
SIC
  • 2800Chemicals And Allied Products
  • 8000Health Services
  • 2830Drugs
  • 8040Offices And Clinics Of Other Health Practitioners
  • 2834Pharmaceutical Preparations
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified